Target intelligence / Profile preview

Splicing factor U2AF 65 kDa subunit (U2AF2)

Target
U2AF2
Molecular classification
RNA-binding protein, Non-snRNP splicing factor, Spliceosome component
01

Overview

Splicing factor U2AF 65 kDa subunit (U2AF2) is a key RNA-binding protein essential for pre-mRNA splicing in eukaryotes[1][2]. U2AF2 forms a heterodimer with U2AF1 and is required for the recognition of the polypyrimidine (Py) tract at the 3′ splice site of introns during spliceosome assembly[1][2]. The protein contains three RNA recognition motifs (RRMs) and an arginine/serine-rich (RS) domain, binding to uridine-rich sequences and establishing protein–protein interactions with other splicing factors such as SF1 and UAP56[1]. U2AF2’s activity is critical for spliceosome fidelity—it proofreads and selects strong Py-tracts while disfavoring weak, non-bona fide splice sites; dysregulation of its assembly or RNA binding results in alternative splicing errors[2][3]. Mutations in U2AF2 have been implicated in various cancers, developmental syndromes, retinal disease, cystic fibrosis, and autoimmune conditions[2]. While U2AF2 is not a conventional drug target or receptor, understanding its function is vital for research into RNA biology and the molecular basis of pre-mRNA splicing diseases[1][2][3].

Other names
U2AF65hU2AF65U2AF^65^U2 auxiliary factor 65 kDa subunitU2 snRNP auxiliary factor large subunitSplicing factor U2AF 65 kD subunitU2 small nuclear ribonucleoprotein auxiliary factor (65kD)DEVDFBU2 (RNU2) small nuclear RNA auxiliary factor 2
02

Biological functions

Pre-mRNA splicingRecognition of polypyrimidine tract at 3′ splice siteSpliceosome assemblyRNA binding
03

Disease associations

Cancer (mutations observed in several cancers)Developmental disorders (de novo mutations associated)Retinitis pigmentosa (mutation in binding sites)Autism spectrum disorder (disrupted association with PTEN)Cystic fibrosis (mutations affecting splicing)Autoimmune disorders (regulation of IL7R exon in multiple sclerosis)
04

Safety considerations

no approved therapies targeting U2AF2theoretical concern includes potential widespread disruption of splicing if targeted

Beyond the preview

Go deeper on Splicing factor U2AF 65 kDa subunit (U2AF2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Splicing factor U2AF 65 kDa subunit (U2AF2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call